RAC1 and melanoma: This idea was experimentally validated in all cell lines expressing oncogenic forms of RAC1. This result is potentially important, as RAC1 oncogenic mutations occur in 5 to 10% of melanoma patients.34,35 No targeted therapy is currently available for these patients.